Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 435 JPY -1.11% Market Closed
Market Cap: 127.7B JPY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Torii Pharmaceutical Co Ltd stock under the Base Case scenario is hidden JPY. Compared to the current market price of 4 435 JPY, Torii Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Torii Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
12
vs Industry
49
Median 3Y
1.9
Median 5Y
1.9
Industry
2.4
Forward
1.9
More Details
24.7
P/E
P/E
Price to Earnings
24.7
vs History
38
vs Industry
18
Median 3Y
23.3
Median 5Y
23.5
Industry
20.6
Forward
22.3
More Details
34.3
P/OCF
P/OCF
Price to OCF
34.3
vs History
44
vs Industry
12
Median 3Y
36.1
Median 5Y
33.7
Industry
15.5
More Details
39.3
P/FCFE
P/FCFE
Price to FCFE
39.3
vs History
33
vs Industry
13
Median 3Y
41.8
Median 5Y
-7
Industry
23
More Details
1
P/B
P/B
Price to Book Value
1
vs History
6
vs Industry
59
Median 3Y
0.9
Median 5Y
0.8
Industry
1.9
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
6
vs Industry
61
Median 3Y
1.1
Median 5Y
1
Industry
2.5
Forward
1.2
More Details
3.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.1
vs History
6
vs Industry
56
Median 3Y
2.4
Median 5Y
1.9
Industry
4.9
More Details
11.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.3
vs History
17
vs Industry
29
Median 3Y
10.1
Median 5Y
8.6
Industry
12.6
Forward
9.9
More Details
12
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12
vs History
23
vs Industry
32
Median 3Y
10.9
Median 5Y
9.4
Industry
15.7
More Details
22.4
EV/OCF
EV/OCF
Enterprise Value to OCF
22.4
vs History
33
vs Industry
18
Median 3Y
17.5
Median 5Y
14.6
Industry
14
More Details
23.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23.6
vs History
23
vs Industry
19
Median 3Y
19.8
Median 5Y
0.9
Industry
17.7
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
6
vs Industry
57
Median 3Y
0.7
Median 5Y
0.6
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Torii Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Torii Pharmaceutical Co Ltd
TSE:4551
124.7B JPY 2.1 24.7 11.3 12
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.2B CHF 4.4 18.9 11.4 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.1 192.6
US
Merck & Co Inc
NYSE:MRK
209.5B USD 3.3 12.2 8.3 9.8
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.2B EUR 2.6 20.1 8.7 12.8
P/E Multiple
Earnings Growth PEG
JP
Torii Pharmaceutical Co Ltd
TSE:4551
Average P/E: 27.3
24.7
17%
1.5
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12.2
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
20.1
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Torii Pharmaceutical Co Ltd
TSE:4551
Average EV/EBITDA: 395.7
11.3
16%
0.7
US
Eli Lilly and Co
NYSE:LLY
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.1
9%
14
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
8.7
6%
1.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Torii Pharmaceutical Co Ltd
TSE:4551
Average EV/EBIT: 1 699.2
12
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.6
21%
9.2
US
Merck & Co Inc
NYSE:MRK
9.8
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
12.8
14%
0.9

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 248,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.